<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The p53 gene is currently thought to be a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene, and its alterations have been suggested to be involved in the pathogenesis of several human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, including some <z:hpo ids='HP_0001909'>leukemias</z:hpo> and <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We present here evidence for the possible involvement of p53 gene mutations in the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), although the incidence is relatively low </plain></SENT>
<SENT sid="2" pm="."><plain>Forty-four patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and six patients with overt <z:hpo ids='HP_0001909'>leukemias</z:hpo> that developed from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> were studied for p53 gene alterations using reverse transcriptase-polymerase chain reaction, single-strand conformation polymorphism analysis, and nucleotide sequencing </plain></SENT>
<SENT sid="3" pm="."><plain>Three patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (2 RAEB and 1 RAEB in T) had missense point mutations in the conserved regions of the p53 coding sequence </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, expression of the <z:mp ids='MP_0002169'>wild-type</z:mp> p53 <z:chebi fb="2" ids="33699">mRNA</z:chebi> was not detected in these three patients </plain></SENT>
<SENT sid="5" pm="."><plain>The probable absence of <z:mpath ids='MPATH_458'>normal</z:mpath> p53 function in the three cases studied here suggests that alterations in the p53 gene may occasionally play a role in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>These three <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with p53 gene mutations and an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-derived <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">erythroleukemia</z:e> cell line that we had previously reported to carry a p53 gene mutation showed no N-ras gene mutations, suggesting <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> in the oncogenic mechanism of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>